- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.12. | Business transacted at the extraordinary general meeting of Aquaporin A/S | 246 | PR Newswire | Company announcementNo. 20/2025Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany reg. no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 1, 2025 /PRNewswire/ -- Aquaporin A/S... ► Artikel lesen | |
| AQUAPORIN Aktie jetzt für 0€ handeln | |||||
| 01.12. | Aquaporin A/S: Business transacted at the extraordinary general meeting of Aquaporin A/S | 93 | GlobeNewswire (Europe) | Company announcement
No. 20/2025
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company reg. no.: DK28315694
Kongens Lyngby, Denmark, December 1, 2025 - Aquaporin A/S ("Aquaporin"... ► Artikel lesen | |
| 13.11. | Aquaporin A/S: Aquaporin Q3 2025 Trading Statement | 181 | PR Newswire | Company announcement
No. 19/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11. | Aquaporin A/S: Notice to convene an extraordinary general meeting | 375 | PR Newswire | Company announcement
No. 18/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11. | Aquaporin A/S: Update on strategic review and intention to strengthen financial position | 327 | PR Newswire | Company announcement
No. 17/2025Inside information
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS... ► Artikel lesen | |
| 21.08. | Aquaporin A/S: Aquaporin announces results for first half 2025 | 349 | PR Newswire | Company announcement No. 16/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngby aquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug. 21, 2025 /PRNewswire/... ► Artikel lesen | |
| 13.08. | AQUAPORIN A/S: Aquaporin to host half-year 2025 results webcast on August 21 | 3 | Cision News | ||
| 12.08. | Aquaporin Cuts FY Revenue Guidance, Initiates Strategic Review | 1 | RTTNews | ||
| 11.08. | Aquaporin A/S: Aquaporin lowers revenue guidance for 2025, but maintains EBITDA guidance, and initiates strategic review | 1.098 | PR Newswire | Company announcementNo. 15/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug.... ► Artikel lesen | |
| 05.08. | Aquaporin A/S: Aquaporin successfully achieves up to 20% energy savings at Kranji NEWater Factory | 339 | PR Newswire | KONGENS LYNGBY, Denmark, Aug. 5, 2025 /PRNewswire/ -- Aquaporin has successfully completed the Living Lab Project to develop the world's first biomimetic low-energy Aquaporin Inside® CLEAR... ► Artikel lesen | |
| 08.07. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons discharging managerial responsibilities | 2 | Cision News | ||
| 07.07. | AQUAPORIN A/S: Aquaporin issues warrants under a new warrant program | 2 | Cision News | ||
| 20.06. | AQUAPORIN A/S: Major shareholder announcement | 2 | Cision News | ||
| 20.06. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons closely associated with persons discharging managerial responsibilities in Aquaporin | 2 | Cision News | ||
| 12.06. | Aquaporin A/S: Aquaporin appoints Chief Executive Officer | 451 | PR Newswire | Company announcementNo. 09/2025
Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark... ► Artikel lesen | |
| 21.05. | Aquaporin A/S: Aquaporin Q1 2025 Trading Statement - maintains full-year financial guidance for 2025 | 355 | PR Newswire | Company announcementNo. 08/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark , May 21, 2025 /PRNewswire/... ► Artikel lesen | |
| 11.04. | Aquaporin A/S - Admittance to trading and official listing of new shares due to exercise of warrants | 207 | GlobeNewswire | The share capital of Aquaporin A/S has been increased. The admittance of trading and official listing of new shares will take effect as per 14 April 2025 in the ISIN below.
ISIN:
DK0061555109
Name:
Aquaporin
Volume... ► Artikel lesen | |
| 20.03. | Aquaporin A/S: Aquaporin announces full-year 2024 results | 622 | PR Newswire | Company announcementNo. 03/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, March 20, 2025 /PRNewswire/... ► Artikel lesen | |
| 20.03. | Aquaporin A/S: Aquaporin announces guidance for 2025 | 187 | GlobeNewswire (Europe) | Company announcement
No. 02/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, March 20, 2025 -... ► Artikel lesen | |
| 26.02. | Aquaporin A/S: Aquaporin improves EBIT and specifies revenue guidance for 2024 | 169 | GlobeNewswire (Europe) | Company announcement
No. 01/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, February 26, 2025... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 66,74 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron | Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,88 | -7,87 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis | KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation... ► Artikel lesen | |
| VOR BIOPHARMA | 10,700 | 0,00 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 38,530 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| ARCELLX | 70,84 | -4,37 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| VERA THERAPEUTICS | 44,660 | -0,82 % | Vera Therapeutics prices public offering to raise $261M at $42.50 a share | ||
| ADMA BIOLOGICS | 19,800 | +2,11 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,30 | +0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| NURIX THERAPEUTICS | 19,550 | 0,00 % | Nurix stock price target raised to $30 by BTIG on promising cancer drug data | ||
| DYNE THERAPEUTICS | 18,420 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen | |
| IMMUNOVANT | 22,760 | -1,77 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 257,93 | -4,82 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,015 | 0,00 % | Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? | ||
| JANUX THERAPEUTICS | 15,740 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| MBX BIOSCIENCES | 28,680 | -8,63 % | Goldman Sachs stuft MBX Biosciences wegen Plattform-Bedenken mit "Sell" ein |
Das Unternehmen AQUAPORIN A/S kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,415 Euro und damit +0,97 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AQUAPORIN A/S finden Sie auf Wallstreet Online.